![](https://webarchive.library.unt.edu/eot2008/20090114233148im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20090114233148im_/http://www.cancer.gov/images/spacer.gif)
DC-OVA vaccine An autologous, multivalent dendritic cell vaccine targeting ovarian cancer with potential immunostimulating and antineoplastic activities. DC-OVA vaccine is produced in vitro by pulsing autologous dendritic cells with killed autologous primary ovarian tumors as a source of tumor-associated antigens (TAAs); the pulsed DCs are then matured using various cytokines. Upon administration, DC-OVA vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against ovarian cancer TAA-expressing ovarian cancer cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20090114233148im_/http://www.cancer.gov/images/spacer.gif)
Abbreviation: | ![](https://webarchive.library.unt.edu/eot2008/20090114233148im_/http://www.cancer.gov/images/spacer.gif) | DC-OVA | | ![](https://webarchive.library.unt.edu/eot2008/20090114233148im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20090114233148im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090114233148im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20090114233148im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20090114233148im_/http://www.cancer.gov/images/spacer.gif) |